Clinical trials: Esophagus Neoplasms
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Advanced Solid Tumor, Sarcoma
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer
- Trial name
- NCT05602792
- Testing
- T3011
- Where
- 19 sites in China
- Volunteers
- 233 people
- Sponsor
- ImmVira Pharma Co. Ltd
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Barrett Esophagus, Esophageal Dysplasia
trūFreeze® Spray Cryotherapy Patient Registry
To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.
- Conditions
- Barrett Esophagus, Esophageal Dysplasia, Esophageal Neoplasm, Esophageal Stenosis
- Trial name
- NCT01802203
- Testing
- truFreeze Spray Cryotherapy
- Where
- 16 sites in United States
- Volunteers
- 275 people
- Sponsor
- US Endoscopy Group Inc.
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study…
- Trial name
- NCT03789617
- Testing
- EBViNT Cell
- Where
- 8 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Eutilex
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Barrett's Esophagus, Esophageal Cancer
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.
- Trial name
- NCT01293448
- Testing
- Cryoballoon Ablation
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 21 people
- Sponsor
- Pentax Medical
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Localized Squamous Cell Carcinoma of the Esophagus
A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus
Investigator will assign 53 patients who had been histologically proven localized squamous cell carcinoma of esophagus to receive the induction chemotherapy regimen of ND-420 50 mg/m2 on day 1, cisplatin 70 mg/m2 on day1, plus…
- Trial name
- NCT02017600
- Testing
- ND-420, Surgery, Cisplatin
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT03122548
- Testing
- CRS-207, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Aduro Biotech, Inc.
Stomach Neoplasms
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG 337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal adenocarcinoma or other MET amplified solid…
- Trial name
- NCT02016534
- Testing
- AMG 337
- Where
- 97 sites in United States, Australia and 16 more
- Volunteers
- 60 people
- Sponsor
- Amgen
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Barrett's Esophagus, Esophageal Cancer
CryoSpray Ablation (TM) GI Patient Registry
The purpose of this study is to create a patient registry to collect and analyze post-510K approval information on subjects treated endoscopically with the CryoSpray Ablation™ System.
- Trial name
- NCT00747448
- Where
- 6 sites in United States
- Volunteers
- 199 people
- Sponsor
- CSA Medical, Inc.